Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating on January 13.Stay Ahead of the ...

Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2025 strategic priorities across its pipeline of mRNA cell ...

FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA ...

Cartesian Therapeutics’ rivals have higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating ...